pdufa.bio
CalendarDecisionsReadoutsPatents
Drug IndexStocksScreenerConferencesAdvisory Committees
StudiesRun-up by YearLearnGlossaryMethodologyAPIAccount
Pro
Home › PDUFA Calendar › RHHBY

RHHBY PDUFA Date: Lunsumio + Polivy

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET
✓ Approved · the FDA decided this application on December 22, 2025. Decision page with the source and measured reaction.
FDA decision Approved December 22, 2025 · Roche Holding AG ADR · 2L+ Diffuse Large B-Cell Lymphoma (DLBCL)
More Cancer & Oncology FDA decisions →All December 2026 PDUFA dates →

The story

Lunsumio + Polivy was approved by the FDA on December 22, 2025 to treat 2L+ Diffuse Large B-Cell Lymphoma (DLBCL).
Full PDUFA calendar ->Every upcoming FDA decision date, by monthLNTH-lnth-2501 . 2026-06-29Same area: Oncology . LNTH-2501 (Gallium-68 edotreotide)AZN-truqap . 2026-06-30Same area: Oncology . TruqapEXEL . 2026-12-03Same month decision . XL092 with atezolizumab
Plain-English summary compiled by pdufa.bio from public FDA, SEC and company sources. Informational only - not investment advice.

RHHBY run-up into the PDUFA (last ~120 days)

$60.58$47.39
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA decisionApproved December 22, 2025
Drug / candidateLunsumio + Polivy
Indication2L+ Diffuse Large B-Cell Lymphoma (DLBCL)
CompanyRoche Holding AG ADR
Market-cap tierLarge
Cohort decision-day move (history)±1% median
ClinicalTrials.govNot listed

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

See the full 2026 PDUFA calendar →

FAQ

What did the FDA decide on RHHBY's Lunsumio + Polivy?
The FDA decided RHHBY's (Roche Holding AG ADR) application for Lunsumio + Polivy on December 22, 2025: Approved. pdufa.bio does not hold a sponsor-disclosed goal date for this application. Verify against the linked primary source.
What is RHHBY's drug Lunsumio + Polivy?
Lunsumio + Polivy is Roche Holding AG ADR's drug, approved by the FDA on December 22, 2025 for 2L+ Diffuse Large B-Cell Lymphoma (DLBCL).
What typically happens to a large-cap stock into a PDUFA date?
Historically, large-cap names had a median decision-day move around ±1% (763-PDUFA cohort, 2024-26). This is historical context by market-cap tier, not a prediction for this drug.
Decision-day move · large-cap cohortn=790 · median +0.0% · 50% up
under -30%: 2 of 790 (0%)<-30-30 to -15%: 2 of 790 (0%)-15 to -7%: 6 of 790 (1%)-7 to -3%: 29 of 790 (4%)-3 to +3%: 707 of 790 (89%)±3+3 to +7%: 35 of 790 (4%)+7 to +15%: 5 of 790 (1%)+15 to +30%: 2 of 790 (0%)over +30%: 2 of 790 (0%)>+30
Distribution of next-day % moves after the FDA decision for large-cap PDUFAs (2020–26). Red = down, green = up, blue = flat (±3%). Historical dispersion, not a forecast.